Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.
RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.
An 18-year-old began using Finasteride and Topical Minoxidil for hair loss, later switching to Oral Minoxidil and Dutasteride by age 25. The conversation emphasizes early treatment, potential side effects, and differing opinions on medication effectiveness.
The user stopped finasteride for three months to try for a baby but continued using minoxidil and micro-needling. They are concerned about hair shedding and plan to resume finasteride after the baby is born.
Creatine may increase scalp DHT without affecting serum DHT, potentially speeding up male pattern baldness (MPB) for those genetically prone. Treatments mentioned include Minoxidil, finasteride, and RU58841.